{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:50:50Z","timestamp":1782143450224,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s41030-026-00360-3","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:06:16Z","timestamp":1779203176000},"page":"617-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Characteristics and Healthcare Resource Use among Patients With COVID-19 Receiving Treatment with Nirmatrelvir\/Ritonavir (PAXLOVID\u2122) in the Kingdom of Saudi Arabia"],"prefix":"10.1007","volume":"12","author":[{"given":"Basem M.","family":"Alraddadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem S.","family":"Almaghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Bosaeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Hassanien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haridy","family":"Hammam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu Karakuzu","family":"Ikizler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence Lefebvre","family":"d\u2019Hellencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Regazzini","family":"Spinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe H.","family":"Kyaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"360_CR1","unstructured":"World Health Organization. Coronavirus disease (COVID-19) [Internet]. 2024 [cited 22 November 2024]. Available from: https:\/\/www.who.int\/health-topics\/coronavirus#tab=tab_1."},{"key":"360_CR2","unstructured":"World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 51. World Health Organization, 2020."},{"issue":"7","key":"360_CR3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S2213-2600(23)00217-5","volume":"11","author":"T Burki","year":"2023","unstructured":"Burki T. WHO ends the COVID-19 public health emergency. Lancet Respir Med. 2023;11(7):588. https:\/\/doi.org\/10.1016\/S2213-2600(23)00217-5.","journal-title":"Lancet Respir Med"},{"key":"360_CR4","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) dashboard > cases [Internet]. 2024 [cited 22 November 2024]. Available from: https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c."},{"key":"360_CR5","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) dashboard > Deaths [Internet]. 2024 [cited 22 November 2024]. Available from: https:\/\/data.who.int\/dashboards\/covid19\/deaths?n=c."},{"key":"360_CR6","unstructured":"Johns Hopkins Medicine. COVID symptoms [Internet]. 2022 [cited 11 October 2022]. Available from: https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/coronavirus\/coronavirus-symptoms-frequently-asked-questions."},{"issue":"1","key":"360_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40246-022-00392-1","volume":"16","author":"M Biancolella","year":"2022","unstructured":"Biancolella M, Colona VL, Mehrian-Shai R, Watt JL, Luzzatto L, Novelli G, et al. COVID-19 2022 update: transition of the pandemic to the endemic phase. Hum Genomics. 2022;16(1):19.","journal-title":"Hum Genomics"},{"key":"360_CR8","unstructured":"National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. [cited 11 October 2022]. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"360_CR9","unstructured":"SingleCare. Coronavirus symptoms and incubation period [Internet]. [cited Oct 11 2022]. Available from: https:\/\/www.singlecare.com\/blog\/news\/coronavirus-symptoms-and-incubationperiod\/."},{"issue":"13","key":"360_CR10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72\u202f314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239\u201342. https:\/\/doi.org\/10.1001\/jama.2020.2648. (PubMed PMID: 32091533).","journal-title":"JAMA"},{"key":"360_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-med-042420-110629","volume":"73","author":"JC Ginestra","year":"2022","unstructured":"Ginestra JC, Mitchell OJL, Anesi GL, Christie JD. COVID-19 critical illness: a data-driven review. Annu Rev Med. 2022;73:95\u2013111. https:\/\/doi.org\/10.1146\/annurev-med-042420-110629.","journal-title":"Annu Rev Med"},{"issue":"2","key":"360_CR12","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.chest.2020.10.014","volume":"159","author":"E Tan","year":"2021","unstructured":"Tan E, Song J, Deane AM, Plummer MP. Global impact of Coronavirus Disease 2019 infection requiring admission to the ICU: a systematic review and meta-analysis. Chest. 2021;159(2):524\u201336. https:\/\/doi.org\/10.1016\/j.chest.2020.10.014. (Epub 20201015).","journal-title":"Chest"},{"issue":"3","key":"360_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/ccm.0000000000004879","volume":"49","author":"JP Domecq","year":"2021","unstructured":"Domecq JP, Lal A, Sheldrick CR, Kumar VK, Boman K, Bolesta S, et al. Outcomes of patients with Coronavirus Disease 2019 receiving organ support therapies: the International Viral Infection and Respiratory Illness Universal Study Registry. Crit Care Med. 2021;49(3):437\u201348. https:\/\/doi.org\/10.1097\/ccm.0000000000004879.","journal-title":"Crit Care Med"},{"key":"360_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1985","volume":"369","author":"AB Docherty","year":"2020","unstructured":"Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20\u2009133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985. https:\/\/doi.org\/10.1136\/bmj.m1985. (Epub 20200522).","journal-title":"BMJ"},{"issue":"20","key":"360_CR15","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","volume":"323","author":"S Richardson","year":"2020","unstructured":"Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052\u20139. https:\/\/doi.org\/10.1001\/jama.2020.6775.","journal-title":"JAMA"},{"key":"360_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cytogfr.2023.11.005","volume":"76","author":"TH Senevirathne","year":"2024","unstructured":"Senevirathne TH, Wekking D, Swain JWR, Solinas C, De Silva P. COVID-19: from emerging variants to vaccination. Cytokine Growth Factor Rev. 2024;76:127\u201341. https:\/\/doi.org\/10.1016\/j.cytogfr.2023.11.005.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"360_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00281-023-00996-2","volume":"45","author":"F Krammer","year":"2024","unstructured":"Krammer F. The role of vaccines in the COVID-19 pandemic: what have we learned? Semin Immunopathol. 2024;45(4):451\u201368. https:\/\/doi.org\/10.1007\/s00281-023-00996-2.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"360_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08754-3","volume":"24","author":"X Wu","year":"2024","unstructured":"Wu X, Xu K, Zhan P, Liu H, Zhang F, Song Y, et al. Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis. BMC Infect Dis. 2024;24(1):234. https:\/\/doi.org\/10.1186\/s12879-023-08754-3. (Epub 20240221).","journal-title":"BMC Infect Dis"},{"issue":"2","key":"360_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/cid\/ciae132","volume":"79","author":"NK Shrestha","year":"2024","unstructured":"Shrestha NK, Burke PC, Nowacki AS, Gordon SM. Effectiveness of the 2023-2024 formulation of the COVID-19 messenger RNA vaccine. Clin Infect Dis. 2024;79(2):405\u201311. https:\/\/doi.org\/10.1093\/cid\/ciae132.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"360_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01724-w","volume":"8","author":"D Ao","year":"2023","unstructured":"Ao D, He X, Liu J, Xu L. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period. Signal Transduct Target Ther. 2023;8(1):466. https:\/\/doi.org\/10.1038\/s41392-023-01724-w. (Epub 20231221).","journal-title":"Signal Transduct Target Ther"},{"key":"360_CR21","unstructured":"U.S. Food and Drug Administration. FDA updates on paxlovid for health care providers [Internet]. 04 May 2022 [cited 11 October 2022]. Available from: https:\/\/www.fda.gov\/drugs\/news-eventshuman-drugs\/fda-updates-paxlovid-health-care-providers."},{"key":"360_CR22","unstructured":"Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals [Internet]. 5 December 2022 [cited 27 January 2023]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html."},{"key":"360_CR23","unstructured":"National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19 [Internet]. 2022 [cited 10 July 2022]. Available from: https:\/\/app.magicapp.org\/#\/guideline\/L4Qb5n\/section\/EgaGN7."},{"key":"360_CR24","unstructured":"European Medicines Agency. Paxlovid [Internet]. 2022 [cited 11 October 2022]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid."},{"key":"360_CR25","unstructured":"Italian Medicines Agency. Use of antivirals for COVID-19 [Internet]. 2022 [cited 11 October 2022]. Available from: https:\/\/aifa.gov.it\/uso-degli-antivirali-orali-per-covid-19."},{"key":"360_CR26","unstructured":"Ministry of Health, Kingdom of Saudi Arabia. Saudi MoH protocol for patients suspected of\/confirmed with COVID-19 [Internet]. 29 September 2022 [cited 02 March 2023]. Available from: https:\/\/www.moh.gov.sa\/Ministry\/MediaCenter\/Publications\/Documents\/MOHtherapeutic-protocol-for-COVID-19.pdf."},{"key":"360_CR27","unstructured":"Ministry of Health, Kingdom of Bahrain. The Kingdom of Bahrain authorises the emergency use of oral COVID-19 Antiviral, Paxlovid [Internet]. 2022 [cited 11 October 2022]. Available from: https:\/\/healthalert.gov.bh\/en\/article\/News-627017."},{"key":"360_CR28","unstructured":"Saudi Food and Drug Authority. PAXLOVID conditional marketing approval (CMA) dosing and dispensing in moderate renal impairment, and risk of serious adverse reactions due to drug interactions [Internet]. 2022."},{"issue":"9","key":"360_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac174","volume":"9","author":"T Pepperrell","year":"2022","unstructured":"Pepperrell T, Ellis L, Wang J, Hill A. Barriers to worldwide access for Paxlovid, a new treatment for COVID-19. Open Forum Infect Dis. 2022;9(9):ofac174. https:\/\/doi.org\/10.1093\/ofid\/ofac174. (Epub 20220407).","journal-title":"Open Forum Infect Dis"},{"key":"360_CR30","unstructured":"Pfizer Inc. Pfizer announces additional phase 2\/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death [Internet]. 2021 [cited 14 December 2021]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announcesadditional-phase-23-study-results"},{"key":"360_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2713","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase E. Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713. https:\/\/doi.org\/10.1136\/bmj.n2713. (Epub 20211108.).","journal-title":"BMJ"},{"key":"360_CR32","unstructured":"Ministry of Health, Kingdom of Saudi Arabia. Ritonavir - boosted Nirmatrelvir (Paxlovid\u00ae) prescribing guidelines for the treatment of COVID-19 (Version 2.0)\u200b [Internet]. 2024."},{"issue":"5","key":"360_CR33","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39234","volume":"15","author":"A Alsaeed","year":"2023","unstructured":"Alsaeed A, Alkhalaf A, Alomran A, Alsfyani W, Alhaddad F, Alhaddad MJ. Paxlovid for treating COVID-19 patients: a case-control study from two hospitals in the Eastern Province of Saudi Arabia. Cureus. 2023;15(5):e39234. https:\/\/doi.org\/10.7759\/cureus.39234.","journal-title":"Cureus"},{"issue":"4","key":"360_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.26719\/emhj.22.008","volume":"28","author":"M Araban","year":"2022","unstructured":"Araban M, Karimy M, Koohestani H, Montazeri A, Delaney D. Epidemiological and clinical characteristics of patients with COVID-19 in Islamic Republic of Iran. East Mediterr Health J. 2022;28(4):249\u201357.","journal-title":"East Mediterr Health J"},{"issue":"5","key":"360_CR35","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.dsx.2020.07.005","volume":"14","author":"N Zaki","year":"2020","unstructured":"Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: a systematic review. DDiabetes Metab Syndr. 2020;14(5):1133\u201342.","journal-title":"DDiabetes Metab Syndr"},{"issue":"1","key":"360_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08944-z","volume":"24","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Zheng H, Xiao G, Xie X, Rang J, Peng D. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study. BMC Infect Dis. 2024;24(1):47. https:\/\/doi.org\/10.1186\/s12879-023-08944-z. (Epub 20240104. PubMed PMID: 38177982; PubMed Central PMCID: PMCPMC10765789.).","journal-title":"BMC Infect Dis"},{"key":"360_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/v15041025","author":"C Del Borgo","year":"2023","unstructured":"Del Borgo C, Garattini S, Bortignon C, Carraro A, Di Trento D, Gasperin A, et al. Effectiveness, tolerability and prescribing choice of antiviral molecules molnupiravir, remdesivir and nirmatrelvir\/r: a real-world comparison in the first ten months of use. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15041025. (Epub 20230421.).","journal-title":"Viruses"},{"issue":"3","key":"360_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083342","volume":"14","author":"A Miyawaki","year":"2024","unstructured":"Miyawaki A, Kitajima K, Iwata A, Sato D, Tsugawa Y. Physician characteristics associated with antiviral prescriptions for older adults with COVID-19 in Japan: an observational study. BMJ Open. 2024;14(3):e083342. https:\/\/doi.org\/10.1136\/bmjopen-2023-083342.","journal-title":"BMJ Open"},{"issue":"2","key":"360_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/cid\/ciad504","volume":"78","author":"CA Gentry","year":"2023","unstructured":"Gentry CA, Nguyen PN, Thind SK, Kurdgelashvili G, Williams RJ II. Characteristics and outcomes of US veterans with immunocompromised conditions at high risk of SARS-CoV-2 infection with or without receipt of oral antiviral agents. Clin Infect Dis. 2023;78(2):330\u20137. https:\/\/doi.org\/10.1093\/cid\/ciad504.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"360_CR40","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jinf.2023.01.018","volume":"86","author":"CA Gentry","year":"2023","unstructured":"Gentry CA, Nguyen PN, Thind SK, Kurdgelashvili G, Williams RJ. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. J Infect. 2023;86(3):248\u201355. https:\/\/doi.org\/10.1016\/j.jinf.2023.01.018. (Epub 20230124.).","journal-title":"J Infect"},{"issue":"7","key":"360_CR41","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/s1473-3099(23)00118-4","volume":"23","author":"JA Lewnard","year":"2023","unstructured":"Lewnard JA, McLaughlin JM, Malden D, Hong V, Puzniak L, Ackerson BK, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis. 2023;23(7):806\u201315. https:\/\/doi.org\/10.1016\/s1473-3099(23)00118-4. (Epub 20230315.).","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"360_CR42","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/s1473-3099(23)00011-7","volume":"23","author":"NR Aggarwal","year":"2023","unstructured":"Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023;23(6):696\u2013705. https:\/\/doi.org\/10.1016\/s1473-3099(23)00011-7. (Epub 20230210.).","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"360_CR43","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.7326\/m23-1756","volume":"176","author":"GE Edelstein","year":"2023","unstructured":"Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, et al. SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy\u202f: an observational study. Ann Intern Med. 2023;176(12):1577\u201385. https:\/\/doi.org\/10.7326\/m23-1756. (Epub 20231114.).","journal-title":"Ann Intern Med"},{"issue":"42","key":"360_CR44","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e347","volume":"38","author":"JJ Park","year":"2023","unstructured":"Park JJ, Kim H, Kim YK, Lee SS, Jung E, Lee JS, et al. Effectiveness and adverse events of nirmatrelvir\/ritonavir versus molnupiravir for COVID-19 in outpatient setting: Multicenter prospective observational study. J Korean Med Sci. 2023;38(42):e347. https:\/\/doi.org\/10.3346\/jkms.2023.38.e347. (Epub 20231030.).","journal-title":"J Korean Med Sci"},{"key":"360_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/v15030811","author":"Y Mutoh","year":"2023","unstructured":"Mutoh Y, Umemura T, Nishikawa T, Kondo K, Nishina Y, Soejima K, et al. Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir\/ritonavir in high-risk patients with COVID-19 in a community setting. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15030811. (Epub 20230322).","journal-title":"Viruses"},{"issue":"1","key":"360_CR46","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12016-022-08921-5","volume":"64","author":"J-j Zhang","year":"2023","unstructured":"Zhang J-j, Dong X, Liu G-h, Gao Y-d. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol. 2023;64(1):90\u2013107. https:\/\/doi.org\/10.1007\/s12016-022-08921-5.","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00360-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00360-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00360-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:24:32Z","timestamp":1782141872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00360-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00360-3","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following conflict of interest: B.A. (Basem Alraddadi) received funding for this project from Pfizer, R.A. (Reem S. AlMaghrabi) received funding for this project from Pfizer, M.B. (Mohamed Bosaeed) received funding for this project from Pfizer, M.K. (Mohamed Kamal) has no conflicts to declare, A.H. (Ashraf Hassanien), H.H. (Haridy Hammam), G.Z. (Giovanni Zanotti), B.K.I. (Burcu Karakuzu Ikizler), F.L.H. (Florence Lefebvre d'Hellencourt, J.R.S. (Julia Regazzini Spinardi), L.W. (Lu Wang), and M.H.K. (Moe H Kyaw) are Pfizer employees at the time of research. Florence Lefebvre d'Hellencourt changed affiliation to CHU La R\u00e9union, France at the time of manuscript publication. The funder had a role in the design of the study; in the collection, analyses, and interpretation of data; in the writing of the manuscript; and in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Ethical approval for the protocol was provided from all three sites\u2019 institutional review boards (study approval code 2023\u201335 from Research Ethics Committee KFSH&RC\u2013Jeddah, study approval code 2231148 from Research Ethics Committee KFSH&RC\u2013Riyadh, and study approval SRC23R\/007\/004 from King Abdullah International Medical Research Center (KAIMRC) IRB). As this study involves anonymized structured data, written informed consent for participation was not required in accordance with the national legislation and the institutional requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors would like to thank all the patients participating in this study and the healthcare personnel who provided care and contributed to patient data collection at National Guard Hospital\u2013Riyadh, King Faisal Specialist Hospital and Research Center\u2013Riyadh, and King Faisal Specialist Hospital and Research Center\u2013Jeddah.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and Site Participation"}}]}}